SCHEMBL5355261

SCHEMBL5355261

CC(C)NCc1cccc(NC(=O)Nc2csc(-c3ncc(C(C)(C)C)o3)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 8/20 0.38
CDK5R1 Q15078 8/20 0.38
SYK P43405 1/20 0.33
GPR142 Q7Z601 1/20 0.33
CDK2 P24941 7/20 0.33
CCNA2 P20248 4/20 0.33
CCNA1 P78396 4/20 0.33
CCNB2 O95067 3/20 0.33
CCNE2 O96020 3/20 0.33
CDK1 P06493 3/20 0.33
CCNB1 P14635 3/20 0.33
CCNE1 P24864 3/20 0.33
CCNB3 Q8WWL7 3/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
RAB9A P51151 2/20 0.32
TRPV3 Q8NET8 2/20 0.32
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5352973 0.82 CDK5 (0.34) CDK5CDK5R1SYKCDK2CCNA2
SCHEMBL5346887 0.80 CDK5 (0.52) CDK5CDK5R1GPR142CDK2CCNA2
SCHEMBL5341625 0.79 CDK5 (0.58) CDK5CDK5R1GPR142CDK2CCNA2
SCHEMBL5343116 0.79 P2RY1 (0.41) CDK5CDK5R1SYKCDK2CCNA2
SCHEMBL5342742 0.78 RAB9A (0.40) CDK5CDK5R1SYKCDK2CCNA2
SCHEMBL5348819 0.74 FLT3 (0.38) CDK5CDK5R1CDK2CCNA2CCNA1
SCHEMBL5338968 0.69 CDK5 (0.52) CDK5CDK5R1GPR142CDK2CCNA2
SCHEMBL5343066 0.68 CDK5 (0.51) CDK5CDK5R1GPR142CDK2CCNA2
SCHEMBL5342307 0.68 CDK5 (0.62) CDK5CDK5R1GPR142CDK2CCNA2
SCHEMBL5338421 0.67 CDK5 (0.61) CDK5CDK5R1GPR142CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1483263-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2004-12-08 EP disclosed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 US disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
WO-2003070727-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2003-08-28 WO disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX CDK5 64/4885CDK5R1 359/4885SYK 2341/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX CDK5 64/4885CDK5R1 359/4885SYK 2341/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX CDK5 64/4885CDK5R1 359/4885SYK 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.